{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-080641","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.342552+00:00","generated_at":"2026-06-04T06:42:34.410393+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Zymeworks appoints Dr. Neil Gallagher to board; 6th new director in 12 months","bullets":["Dr. Gallagher joins board effective April 2, 2024 as Class I director, term to 2025 AGM.","He will receive initial option grant for 74,000 common shares on appointment.","Gallagher appointed to R&D committee; full committee composition updated (see filing).","Gallagher is President & Head of R&D at Syndax Pharmaceuticals; ex-AbbVie, Amgen, Novartis.","CEO says appointment supports advancement of '5 by 5' clinical programs and pipeline expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-080641","json":"https://secwatch.observer/filing/0001193125-24-080641.json","markdown":"https://secwatch.observer/filing/0001193125-24-080641.md","text":"https://secwatch.observer/filing/0001193125-24-080641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/0001193125-24-080641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/d803711d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:42:34.410393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7afddb2ec5","claim":"Dr. Neil Gallagher was appointed as director at Zymeworks Inc..","evidence_excerpt":"On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/0001193125-24-080641-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}